BioTools Innovator

Glyphic Biotechnologies is developing a single-molecule-resolution protein sequencing platform

By Samantha Black, PhD, The Science Advisory Board editor in chief

September 7, 2021 -- Glyphic Biotechnologies is developing a novel protein sequencing platform that allows researchers to determine each amino acid in a protein sequence. The company is one of 10 semifinalists in the BioTools Innovator accelerator contest, and we spoke with co-founder and CEO Josh Yang as part of our exclusive coverage of the competition.

Proteins represent an area of drug discovery and development with huge untapped potential, serving as targets for many therapeutics. However, their use cases are limited by cost and technology constraints of existing approaches. Glyphic Biotechnologies is seeking to remove the technology barriers with its novel protein sequencing platform to enable the development of novel diagnostics and therapeutics and provide an enhanced understanding of human biology.

Video loading ...

The company's ClickP technology tethers target amino acids in a given protein sequence, making it much easier to identify and process. Yang explained that his company's technology works at single-molecule resolution and will transform the field beyond what is capable with the use of older technologies such as mass spectrometry and enzyme-linked immunosorbent assays.

Yang stated that Glyphic is competing against some of the biggest names in the industry (Illumina and 454 Life Sciences, which was acquired by Roche), but the founders are dedicated to bringing their product to the proteomics market.

Glyphic Biotechnologies is one of 10 semifinalists that have the chance to win $200,000 in cash prizes in the BioTools Innovator accelerator contest, with the list of semifinalists released in late July. All semifinalists are assigned a mentor and will complete a curated curriculum designed to help them secure additional funding and bring their companies to the next level. The field will be narrowed to four companies in early October. The four finalists will present at a live finale on October 14, where the audience will help decide the winner.

Stay tuned and follow along as we get a behind-the-scenes look at these companies as they race toward the finish!

Disclosure note: The BioTools Innovator accelerator contest is sponsored by Research Corporation Technologies and BroadOak Capital Partners, investors in's parent company, Science and Medicine Group.

How EpiCypher is quantifying and scaling chromatin science
EpiCypher is developing tools based on its designer nucleosome technology to enable epigenetics-focused drug development for a variety of chromatin biology...
Clara Biotech advances exosomes in biomedical research
Clara Biotech sees its exosome purification and isolation technology as a tool that can help biomedical researchers in multiple fields. The company is...
BioTools Innovator selects 10 accelerator semifinalists
BioTools Innovator has selected 10 companies to participate in the organization's inaugural three-month virtual mentorship-focused accelerator program.
BioTools Innovator seeks to boost startups developing life science tools
On-Demand Webinar -- BioTools Innovator is calling for applications to its inaugural competition to advance innovation by accelerating the growth of startups...
MedTech Innovator launches to help life science startups
MedTech Innovator has launched BioTools Innovator, a funding competition to help life science startups develop and commercialize biotechnology products,...

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter